Heterogeneity response to afatinib in gastric cancer patient with uncommon epidermal growth factor receptor (EGFR) mutations: a case report

Despite concerted efforts that have been made to characterize and understand the genomic landscape of gastric cancer (GC), only HER2 has been validated as a molecular target for GC treatment. Identifying new valid therapeutic targets is important for the treatment of this disease. The present report...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qin, Yang, Yang, Fan, Xiangshan, Xin, Xiaoyan, Pan, Qiuyue, Zhang, Yihong, Liu, Baorui, Wei, Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246221/
https://www.ncbi.nlm.nih.gov/pubmed/34268427
http://dx.doi.org/10.21037/atm-20-7312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246221/
https://www.ncbi.nlm.nih.gov/pubmed/34268427
http://dx.doi.org/10.21037/atm-20-7312

Ejemplares similares